FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

July 31 2018 A class 3 recall for sodium cromoglicate 2% w/v eye drops and Murine Hayfever Relief...

Effect of omega-3 on heart disease is negligible, finds Cochrane review

Effect of omega-3 on heart disease is negligible, finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

Welsh National Survey includes OTC medicine purchases for first time

Welsh National Survey includes OTC medicine purchases for first time

June 28 2018 Over half the population in Wales has reported having bought an over the counter...

Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

  • FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    Tuesday, 31 July 2018 15:24
  • Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Thursday, 19 July 2018 10:21
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:32
  • Welsh National Survey includes OTC medicine purchases for first time

    Welsh National Survey includes OTC medicine purchases for first time

    Thursday, 28 June 2018 16:55
  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageMarch 1 2018

The medicines regulator has put out a warning urging people who have purchased Yiganerjing Cream to stop using it immediately. 

The warning was issued after it was found the product contains an undisclosed steroid and two antifungal ingredients. The MHRA has been working to prevent further sales of the product which has been sold mainly through websites and online market places. However, it is concerned that people may have purchased it in the past and will still be using it.

“Yiganerjing Cream is not a licensed medicine and has been marketed in the UK as a ‘natural’ Chinese herbal medicine for the treatment of a range of skin conditions, most commonly eczema, psoriasis and rosacea,” said the MHRA.

“Our analysis found the presence of the steroid clobetasol propionate. This steroid is the active ingredient in Prescription-Only Medicines used for the treatment of a range skin conditions such as psoriasis and eczema. Creams containing steroids should be used sparingly and as directed by the prescriber. It is contraindicated in children under 1 year of age.”

It has also warned of another product, Penny Orange Cream, which has also been found to contain clobetasol propionate. It was marketed via a herbal clinic but has not been available for a while.

The MHRA is asking people if they are aware of Yiganerjing cream being sold, to report it by email to This email address is being protected from spambots. You need JavaScript enabled to view it..

Link:
MHRA announcement

OTC News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...